Dr. Bradford Wood is Chief of IR and directs a multi-disciplinary team (NIH Center for Interventional Oncology) that develops and translates devices, software, and navigation approaches for cancer patients via novel local and regional minimally-invasive image-guided therapies..
Dr. Wood earned undergraduate and graduate degrees from the University of Virginia, internship in internal medicine, and residency in radiology at Georgetown University, where he was Chief Resident.
He did two fellowships at Massachusetts General Hospital at Harvard in Abdominal Imaging and Intervention and Vascular & Interventional Radiology, and stayed on staff there after training.
He is board-certified in Vascular and Interventional Radiology as well as in Diagnostic Radiology, and is a Fellow of the Society of Interventional Radiology.
Dr. Wood has practiced Interventional Radiology at NIH for decades, was Acting Co-Director of Radiology, and Acting Director of the Molecular Imaging Lab in the late 2000’s. He holds appointments in the NIH Clinical Center, the National Cancer Institute, Urological Oncology Branch, NIBIB, and is Adjunct Prof in Biomedical Engineering at the Univ Maryland.
He has received the NIH Director's Awards, NIH Clinical Center Director's Awards, NIH Clinical Center CEO Awards, NIH Bench to Bedside Awards, NIH OD Honor Award, NCI Research Highlights Award, and has co-authored ~ 600 peer-reviewed papers (H-Index = 99) and several books.
Dr. Wood is Chief of IR and founding Director of the NIH Center for Interventional Oncology ((NIH Center for Interventional Oncology) that develops and translates novel devices, software, and navigation approaches for cancer patients within a multi-disciplinary framework. Biomedical engineering is applied to unmet clinical needs via novel local and regional minimally-invasive image-guided therapies.
His team's achievements include helping to pioneer technologies from concept to bench to patient, including “first-in-human” for device/drug combinations, prostate cancer MRI/TRUS fusion biopsy and ablation, image-able iodinated drug eluting beads for chemoembolization, kidney, adrenal and pheochromocytoma cancer ablation, heat-deployed nanoparticle chemotherapy with thermal ablation for liver cancer, electromagnetic tracking for fusion of ultrasound to CT, MR, and PET, and fusion for biopsy and ablation.
Metrics include > 50 patents, books on radiology and interventional urology, > 600 publications (H-index of 99) including JAMA, NEJM, Nature Medicine, Nature Comm, Science, Lancet, Blood, Chest, Cancer, JCO, Clin Cancer Res, Science Translational Medicine, JNCI, JAMA Oncology, Hepatology, Medical Physics, JAMIA and Scientific Reports.
His team's research relies upon multi-disciplinary team science within multiple institutes and international public-private partnerships. His team has mentored hundreds of students, fellows, physicians, nurses, and scientists.
Teamwork and team science breed success.
See his Intramural Research Program bio page.
Harmon SA, Sanford TH, Xu S, Turkbey EB, Roth H, Xu Z, Yang D, Myronenko A, Anderson V, Amalou A, Blain M, Kassin M, Long D, Varble N, Walker SM, Bagci U, Ierardi AM, Stellato E, Plensich GG, Franceschelli G, Girlando C, Irmici G, Labella D, Hammoud D, Malayeri A, Jones E, Summers RM, Choyke PL, Xu D, Flores M, Tamura K, Obinata H, Mori H, Patella F, Cariati M, Carrafiello G, An P, Wood BJ, Turkbey B. Artificial intelligence for the detection of COVID-19 pneumonia on chest CT using multinational datasets. Nat Commun. 2020;11(1):4080.
Ahdoot M, Wilbur AR, Reese SE, Lebastchi AH, Mehralivand S, Gomella PT, Bloom J, Gurram S, Siddiqui M, Pinsky P, Parnes H, Linehan WM, Merino M, Choyke PL, Shih JH, Turkbey B, Wood BJ, Pinto PA. MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis. N Engl J Med. 2020;382(10):917-928.
Greten TF, Mauda-Havakuk M, Heinrich B, Korangy F, Wood BJ: Combined locoregional-immunotherapy for liver cancer. J Hepatol. 2019;70(5):999-1007.
Siddiqui MM, Rais-Bahrami S, Turkbey B, George AK, Rothwax J, Shakir N, Okoro C, Raskolnikov D, Parnes HL, Linehan WM, Merino MJ, Simon RM, Choyke PL, Wood BJ, Pinto PA. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA. 2015;313(4):390-7.
Pinto PA, Chung PH, Rastinehad AR, Baccala AA Jr, Kruecker J, Benjamin CJ, Xu S, Yan P, Kadoury S, Chua C, Locklin JK, Turkbey B, Shih JH, Gates SP, Buckner C, Bratslavsky G, Linehan WM, Glossop ND, Choyke PL, Wood BJ: Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. J Urol. 2011 Oct;186(4):1281-5
NOTE: PDF documents require the free Adobe Reader.
This page last updated on 03/31/2023